The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment

Bortoli, Nicola de; Martinucci, Irene; Giacchino, Maria; Blandizzi, Corrado; Marchi, Santino; Savarino, Vincenzo; Savarino, Edoardo

doi:10.1517/17425255.2013.813018

Cited by 31 publications

(22 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28][29][30] Accordingly, ilaprazole is expected to have a longer duration of action and less NAB compared to other PPIs. 31,32 But we found that GERD symptoms, 24-hour mean gastric pH, nocturnal mean gastric pH, frequency and duration of NAB, were comparable between the ilaprazole and omeprazole groups. The only significant difference was occurrence of lesser number of NAB episodes in the ilaprazole group.…”

Section: Discussionmentioning

confidence: 70%

Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease

Karyampudi

Ghoshal

Singh

et al. 2017

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/AimsThough nocturnal acid-breakthrough (NAB) is common in gastroesophageal reflux disease (GERD) patients, its clinical importance results from esophageal acidification, which has been shown to be uncommon. Ilaprazole, a long-acting proton pump inhibitor, may cause NAB infrequently. Accordingly, we studied prospectively, (1) frequency and degree of esophageal acidification during NAB, and (2) frequency and severity of NAB while on ilaprazole versus omeprazole. MethodsFifty-eight consecutive patients with GERD on once daily ilaprazole, 10 mg (n = 28) or omeprazole, 20 mg (n = 30) for > one month underwent 24-hour impedance-pH monitoring prospectively. NAB was defined as intra-gastric pH < 4 for > one hour during night, and esophageal acidification as pH < 4 for any duration. Nocturnal symptoms (heartburn, regurgitation, and chest pain) were also recorded. Results Of ConclusionsThough NAB was common while patients were on a proton pump inhibitor, esophageal acidification was uncommon. Frequency and severity of NAB were comparable among patients on ilaprazole and omeprazole, except for the lesser number of NABs with ilaprazole.

show abstract

Section: Discussionmentioning

confidence: 70%

Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease

Karyampudi

Ghoshal

Singh

et al. 2017

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…10 Of note, the favourable pharmacokinetic pattern of ilaprazole, relying mainly in a lack of influence by CYP 2 C 19 genetic polymorphism and a prolonged elimination half-life, is expected to impact positively, in terms of lower variability and long lasting acid inhibition, on the inhibition of gastric acid secretion. 11 In this survey, the commonly encountered acid peptic disorders observed were GERD followed by peptic ulcer disease. Commonly reported symptoms of APD are heartburn, regurgitation, abdominal discomfort, nausea, sleep disturbances.…”

Section: Discussionmentioning

confidence: 90%

Prescribing pattern of proton pump inhibitors in the management of acid peptic disorders, focus on ilaprazole

Mayabhate

2016

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

INTRODUCTIONAcid peptic disorders (APDs) are a collective term that includes many conditions such as peptic ulcer disease, GERD and Gastritis. Acid peptic disorders are the result of distinctive, but overlapping pathogenic mechanisms leading to either excessive acid secretion or diminished mucosal defense. The prevalence of gastroesophageal reflux disease (GERD) in India is likely to be between 8% and 19%, which is comparable to GERD prevalence rates published in western countries.2 Peptic ulcer disease (PUD) tends to have a chronic remitting course with imperfect correlation between symptoms and the presence of an ulcer. Each year PUD affects 4 million people around the world. A recent study by Dutta AK et al showed a time trends in epidemiology of peptic ulcer disease in India and observed the frequencies of 2.9% for duodenal ulcer and 2.7% gastric ulcer from 1988 to 2008. The causes of APD include H. Pylori infection, over use of NSAIDS, smoking and alcohol consumption and it is also linked with stress and dietary factors such as spicy and oily food. The increase in incidence of APD in the current scenario can be linked to the present stressful lifestyles. Patients commonly present with nausea, heartburn, dysphagia and abdominal pain. If left ABSTRACT Background: Acid peptic disorders (APDs) result from characteristic but overlapping pathogenic mechanisms that involve acid effects on diminished mucosal defense. Proton pump inhibitors (PPIs) have become a mainstay in the APDs. This survey was aimed to determine the usage profile of different proton pump inhibitors and overall physicians' opinion about the clinical experience with newer PPI, ilaprazole. Methods: This survey was based on the clinical experience of 107 randomly selected physicians on an aggregate patient basis in the management of acidpeptic disorders from different parts of India. A data report form (DRF) comprising of various questions was answered by these physicians. The responding physicians answered the DRF of patients who suffered from acidpeptic disorders and were eligible for PPI therapy. A minimum of 50 patients per physician were evaluated in this survey. Results: The commonly encountered APD in physicians' clinical practice were gastroesophageal reflux disorder (GERD) followed by non-ulcer disease. 58.88% physicians highlighted the prevalence of night time symptoms of APD reported by the patients. About 1/4th physicians were of the opinion that longacting PPIs would be the preferred to offer 24 hour control of gastric acid secretion thereby controlling the nocturnal symptoms. 63.73% of physicians reported significantly better symptomatic relief with once daily dose of ilaprazole than existing PPIs. Conclusions: This survey highlights the lack of 24 hour acid control in APDs with use of conventional PPIs leading to variety of symptoms, especially at night, seriously hampering the sleep quality. Ilaprazole displays important advantages in the clinical settings, with regard to better probability of extending the inhibition of acid secret...

show abstract

“…This is mainly due to a high clarithromycin-resistance rate; however, it is also possible that the cause is a CYP2C19 polymorphism [20]. Ilaprazole is primarily metabolized by CYP3A4 and is not influenced by CYP2C19 genetic polymorphisms [21]. In addition, ilaprazole has a long half-life, which leads to a longer period of gastric acid suppression and higher ulcer healing rates compared with other PPIs.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections

Ahn

Kim

Chu

et al. 2017

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Background and Aims. To establish the efficacy and safety of ilaprazole, levofloxacin, and amoxicillin as a first-line eradication treatment for Helicobacter pylori. Methods. Patients with gastric ulcer, duodenal ulcer, or gastritis, as detected by esophagogastroduodenoscopy with confirmed H. pylori infection between September 2014 and November 2015, were enrolled in the study. All participants received ilaprazole (10 mg bid), levofloxacin (500 mg bid), and amoxicillin (1000 mg bid) for 10 days. H. pylori eradication was confirmed by a 13C-urea breath test at 6–8 weeks after the end of treatment. Results. Of 84 patients included in the analysis, the eradication rate was 88.8% in the per protocol group (n = 80). Demographic factors such as age, gender, body mass index (BMI), alcohol, smoking, hypertension, diabetes mellitus, and peptic ulcer did not affect the eradication rate. However, multivariate analysis showed that overweight patients and patients with cerebrovascular accident (CVA) had a significantly lower eradication rate than patients with normal BMI and without CVA. Laboratory test results did not change significantly after treatment. A total of six (7.5%) patients developed eight adverse reactions. Conclusions. A 10-day triple therapy containing ilaprazole, levofloxacin, and amoxicillin is a safe alternative first-line eradication treatment for H. pylori.

show abstract

The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment

Cited by 31 publications

References 56 publications

Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease

Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease

Prescribing pattern of proton pump inhibitors in the management of acid peptic disorders, focus on ilaprazole

Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections

Contact Info

Product

Resources

About